U.S. markets closed
  • S&P Futures

    4,694.50
    +9.50 (+0.20%)
     
  • Dow Futures

    35,745.00
    +32.00 (+0.09%)
     
  • Nasdaq Futures

    16,367.50
    +49.50 (+0.30%)
     
  • Russell 2000 Futures

    2,258.20
    +4.30 (+0.19%)
     
  • Crude Oil

    71.69
    -0.36 (-0.50%)
     
  • Gold

    1,788.00
    +3.30 (+0.18%)
     
  • Silver

    22.52
    -0.00 (-0.01%)
     
  • EUR/USD

    1.1283
    +0.0010 (+0.09%)
     
  • 10-Yr Bond

    1.4800
    +0.0460 (+3.21%)
     
  • Vix

    21.89
    -5.29 (-19.46%)
     
  • GBP/USD

    1.3246
    +0.0004 (+0.03%)
     
  • USD/JPY

    113.4600
    -0.0800 (-0.07%)
     
  • BTC-USD

    50,475.33
    -212.05 (-0.42%)
     
  • CMC Crypto 200

    1,304.38
    -16.90 (-1.28%)
     
  • FTSE 100

    7,339.90
    +107.62 (+1.49%)
     
  • Nikkei 225

    28,736.86
    +281.26 (+0.99%)
     

Why Axsome Therapeutics Stock Is Crashing Today

·2 min read
Why Axsome Therapeutics Stock Is Crashing Today
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Axsome Therapeutics (NASDAQ: AXSM), a mid-cap biotech, are down by a hefty 41.4% as of 10:08 a.m. EDT Monday morning. The drugmaker's shares are tumbling today in response to a disappointing regulatory update for AXS-05 as a potential treatment for major depressive disorder (MDD). Specifically, Axsome revealed during its 2021 second-quarter earnings release this morning that the U.S. Food and Drug Administration (FDA) had notified the company on July 30, 2021 that it has identified deficiencies within the drug's regulatory application that preclude discussion of labeling and post-marketing requirements at this time.